Genscript Biotech Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Genscript Biotech wird ein jährliches Gewinn- und Umsatzwachstum von 113.4% bzw. 39.2% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 113.8% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 9.5% betragen.

Wichtige Informationen

112.5%

Wachstumsrate der Gewinne

112.3%

EPS-Wachstumsrate

Life Sciences Gewinnwachstum	53.3%
Wachstumsrate der Einnahmen	39.0%
Zukünftige Eigenkapitalrendite	9.5%
Analystenabdeckung	Good
Zuletzt aktualisiert	23 Aug 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

SHSC:1548 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	2,620	254	-49	778	11
12/31/2025	1,791	44	-200	97	12
12/31/2024	1,200	-170	-330	-99	12
6/30/2024	1,010	-177	-276	-20	N/A
3/31/2024	925	-136	-410	-153	N/A
12/31/2023	840	-95	-543	-287	N/A
9/30/2023	773	-140	-506	-266	N/A
6/30/2023	707	-185	-523	-245	N/A
3/31/2023	667	-206	-431	-183	N/A
12/31/2022	626	-227	-339	-120	N/A
9/30/2022	598	-315	-321	-142	N/A
6/30/2022	570	-403	-304	-163	N/A
3/31/2022	530	-381	-289	-150	N/A
12/31/2021	490	-359	-274	-137	N/A
9/30/2021	483	-265	-265	-127	N/A
6/30/2021	454	-183	-256	-118	N/A
3/31/2021	422	-194	-268	-134	N/A
12/31/2020	391	-205	-279	-151	N/A
9/30/2020	354	-194	-171	-48	N/A
6/30/2020	318	-183	-64	54	N/A
3/31/2020	296	-140	-103	12	N/A
12/31/2019	273	-97	-142	-30	N/A
9/30/2019	257	-59	-207	-116	N/A
6/30/2019	241	-22	-272	-202	N/A
3/31/2019	236	0	-18	53	N/A
12/31/2018	231	21	236	308	N/A
9/30/2018	216	24	266	338	N/A
6/30/2018	201	27	297	369	N/A
3/31/2018	177	26	N/A	195	N/A
12/31/2017	153	26	N/A	21	N/A
9/30/2017	139	27	N/A	24	N/A
6/30/2017	125	28	N/A	27	N/A
3/31/2017	120	27	N/A	30	N/A
12/31/2016	115	26	N/A	33	N/A
9/30/2016	107	26	N/A	29	N/A
6/30/2016	99	25	N/A	25	N/A
3/31/2016	93	21	N/A	22	N/A
12/31/2015	87	18	N/A	20	N/A
9/30/2015	82	13	N/A	18	N/A
6/30/2015	78	8	N/A	16	N/A
3/31/2015	74	7	N/A	14	N/A
12/31/2014	70	6	N/A	12	N/A
12/31/2013	60	6	N/A	12	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 1548 wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.3%).

Ertrag vs. Markt: 1548 wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: 1548 wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: 1548Die Einnahmen des Unternehmens (39.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Hong Kong (7.4% pro Jahr).

Hohe Wachstumseinnahmen: 1548Die Einnahmen des Unternehmens (39.2% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 1548Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (9.5%).

Genscript Biotech Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Genscript Biotech Corporation Provides Earnings Guidance for the Six Months Ended June 30, 2022

Genscript Biotech Corporation Provides Earnings Guidance for the Year Ended 31 December 2021

Recent updates

Genscript Biotech Corporation Announces Board Appointments

First half 2024 earnings released: US$0.083 loss per share (vs US$0.044 loss in 1H 2023)

First half 2024 earnings released: US$0.083 loss per share (vs US$0.044 loss in 1H 2023)

Genscript Biotech Corporation to Report First Half, 2024 Results on Aug 09, 2024

New minor risk - Share price stability

Genscript Biotech Corporation Announces Board Resignations and Changes in Composition of Board Committees

GenScript Biotech Corporation Launches FLASH Gene Service: The Most Affordable Gene Synthesis Solution on the Market

Now 22% undervalued after recent price drop

GenScript Biotech Corporation Announces Self-Amplifying RNA Synthesis Service for Advanced Therapeutic Applications

Full year 2023 earnings released: US$0.045 loss per share (vs US$0.11 loss in FY 2022)

Now 25% undervalued after recent price drop

Insider recently sold HK$1.0m worth of stock

Genscript Biotech Corporation Announces Directorate Appointments and Change in Composition of Board Committee

Board Member recently sold HK$455k worth of stock

Genscript Biotech Corporation, Annual General Meeting, May 17, 2024

Full year 2023 earnings released: US$0.045 loss per share (vs US$0.11 loss in FY 2022)

Genscript Announces Appointment of Dr. David R. Liu to the Scientific Advisory Board

Genscript Biotech Corporation to Report Fiscal Year 2023 Final Results on Mar 09, 2024

New minor risk - Profitability

Executive Chairman recently sold HK$610k worth of stock

GenScript Biotech Corporation Expands its IVT mRNA Synthesis Portfolio with Addition of Customized Circular RNA and Lipid Nanoparticles Formulation Services

First half 2023 earnings released: US$0.044 loss per share (vs US$0.063 loss in 1H 2022)

Genscript Biotech Corporation to Report First Half, 2023 Results on Aug 19, 2023

Insider recently sold HK$1.4m worth of stock

Full year 2022 earnings released: US$0.11 loss per share (vs US$0.17 loss in FY 2021)

Now 24% undervalued

Now 20% undervalued

Genscript Biotech Corporation Announces Chief Executive Officer Changes

Genscript Biotech Corporation Announces Redesignation of Dr. Zhang Fangliang from A Non-Executive Director to an Executive Director with Effect from December 17, 2022

Less than half of directors are independent

First half 2022 earnings released: US$0.063 loss per share (vs US$0.046 loss in 1H 2021)

Genscript Biotech Corporation to Report First Half, 2022 Results on Aug 31, 2022

Genscript Biotech Corporation Provides Earnings Guidance for the Six Months Ended June 30, 2022

Genscript Biotech Corporation Announces Board Changes

Genscript Biotech Corporation Announces Board Changes

Full year 2021 earnings released: US$0.17 loss per share (vs US$0.11 loss in FY 2020)

Less than half of directors are independent

Genscript Biotech Corporation, Annual General Meeting, May 27, 2022

Genscript Biotech Corporation Provides Earnings Guidance for the Year Ended 31 December 2021

Board Member recently sold HK$2.1m worth of stock

First half 2021 earnings released: US$0.046 loss per share (vs US$0.06 loss in 1H 2020)

Key Executive recently sold HK$9.1m worth of stock

Duke-NUS Medical School and GenScript Biotech Corporation Announce Notice of Allowance for U.S. Patent Application for SARS-CoV-2 Surrogate Virus Neutralization Test

Hillhouse Capital Management, Ltd. completed the acquisition of 2.99% stake in Genscript Biotech Corporation (SEHK:1548) from GenScript Corporation.

Full year 2020 earnings released: US$0.11 loss per share (vs US$0.052 loss in FY 2019)

Full year 2020 earnings released

Genscript Biotech Corporation to Report Fiscal Year 2020 Results on Mar 26, 2021

New 90-day high: HK$14.66

Genscript Probio and Neoletix Announce Successful Completion of 200-Liter Gmp Production Runs of Recombinant Coagulation Fviii Based on A Novel Production Technology

New 90-day low: HK$10.18

New 90-day low: HK$10.36

Genscript Biotech Corporation Announces Board and Director Changes

New 90-day low: HK$11.38

Co-Founder recently bought HK$3.7m worth of stock

First half earnings released

New 90-day low: HK$11.48

First half earnings released

New 90-day low - HK$14.96

Genscript Biotech Corporation to Report Q2, 2020 Results on Aug 29, 2020

Genscript Biotech Corporation Announces Management Changes Effective 2 August 2020

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken